StreetInsider.com News Articles

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Heading into Q3 earnings of MedTech stocks, analysts at BTIG recommend investors “use any weakness” to their advantage, focusing on names likely to reaccelerate early in 2027, even as the latest quarterly results are expected to face tougher comps as many companies had guided for higher growth in 2H26. Here, one name stands out.

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Buy this MedTech stock on weakness: BTIG

Sat, 17 Oct 2026 10:00:00 -0400

Stryker Corporation (NYSE: SYK) shares are down over 18% YTD, with shares already pricing in a “likely” guidance cut. However, BTIG sees potential for reacceleration in FY27.

“With a CEO announcement behind it and as numbers come down, tax-loss selling offers an opportunity to pick up SYK for

Stryker receives FDA clearance for Sonopet 3 tissue removal platform

Wed, 14 Oct 2026 09:04:52 -0400

Stryker (NYSE: SYK) announced it has received 510(k) clearance from the U.S. Food and Drug Administration for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform.

The Portage, Mich.-based company said Sonopet 3 was developed with input from hundreds of surgeons and is designed to operate as a single platform for tissue removal in neurosurgical settings.

Mitch Foley, vice president and general manager of Stryker's Neurosurgical business, said in a statement: "Every major advancement in Sonopet 3 can be attributed to surgeon feedback, and together we're elevating the standard in neurosurgery. They told us they wanted more power, improved ergonomics

Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal

Wed, 14 Oct 2026 09:03:00 -0400

Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform.
Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.

Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal

Wed, 14 Oct 2026 09:03:00 -0400

Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform.
Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.

Stryker invests $400M in CMR Surgical with option to acquire

Mon, 12 Oct 2026 08:03:20 -0400

Stryker (NYSE: SYK) announced a strategic alliance with CMR Surgical that includes an approximately $400 million (£300 million) preferred equity investment in the Cambridge, England-based robotics company, along with an exclusive option to acquire 100% of CMR Surgical's outstanding equity in the future.

As part of the agreement, Stryker will serve as the exclusive U.S. sales agent for CMR Surgical's Versius surgical robotic portfolio. CMR Surgical will retain responsibility for portfolio development and commercialization in markets outside the United States.

The investment is subject to regulatory approvals and customary closing conditions. Terms of the exclusive acquisition option were not fully disclosed.

Andy Pierce,

Stryker invests $400M in CMR Surgical with option to acquire

Mon, 12 Oct 2026 08:03:20 -0400

The investment is subject to regulatory approvals and customary closing conditions. Terms of the exclusive acquisition option were not fully disclosed.

Andy Pierce,

Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery

Mon, 12 Oct 2026 08:00:00 -0400

Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) --

Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer relationships and commercial reach to accelerate growth of the Versius Surgical Robotic portfolio

Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical to support future innovation and global commercialization of the Versius portfolio, subject to customary closing conditions
The preferred equity investment also grants Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement's

Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery

Mon, 12 Oct 2026 08:00:00 -0400

Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) --

Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical to support future innovation and global commercialization of the Versius portfolio, subject to customary closing conditions
The preferred equity investment also grants Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement's

U.S. MedTech stocks: Q3 earnings preview